Cidara Therapeutics, Inc. (NASDAQ:CDTX – Get Free Report) CEO Jeffrey Stein bought 8,000 shares of the company’s stock in a transaction that occurred on Friday, June 7th. The stock was purchased at an average cost of $13.21 per share, with a total value of $105,680.00. Following the acquisition, the chief executive officer now directly owns […]
Cidara Therapeutics (NASDAQ:CDTX – Get Free Report) and Mesoblast (NASDAQ:MESO – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, valuation, dividends, institutional ownership and analyst recommendations. Insider & Institutional Ownership 35.8% of Cidara Therapeutics […]
Cidara Therapeutics (NASDAQ:CDTX – Get Free Report) and Mesoblast (NASDAQ:MESO – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, institutional ownership, dividends and analyst recommendations. Analyst Ratings This is a summary of current […]
Cidara Therapeutics, Inc. (NASDAQ:CDTX – Get Free Report) has been assigned a consensus rating of “Buy” from the four ratings firms that are covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price […]
Cidara Therapeutics (NASDAQ:CDTX – Get Free Report) and Mesoblast (NASDAQ:MESO – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, dividends, risk, analyst recommendations, earnings and valuation. Institutional & Insider Ownership 35.8% of Cidara Therapeutics […]